FSSAI Challenges Nestle, Zydus Over Infant Formula Health Claims

The Food Safety and Standards Authority of India (FSSAI) has taken enforcement action against Nestle India and Zydus Wellness Limited, directing both companies to provide substantiating evidence for health and nutritional claims made on their infant formula products. The notices specifically reference Lactogen Pro 1 and Nan Excella Pro Stage 1, manufactured by Nestle, as well as Complan produced by Zydus Wellness. Regulators have flagged the promotional messaging as potentially misleading to consumers.

The move reflects heightened scrutiny by India's food safety watchdog over unsubstantiated marketing claims in the infant nutrition sector. Companies are required under FSSAI regulations to back claims with robust scientific data and clinical evidence before marketing their products to consumers. The regulator has asked both manufacturers to submit detailed documentation supporting the specific assertions made in their product advertising and packaging.

This enforcement action is part of a broader regulatory push to protect consumers from misleading health claims in the nutrition category. Infant formula products face particular regulatory attention given their critical role in child nutrition and the vulnerability of the consumer base. The FSSAI's decision to issue formal notices underscores the importance of transparent and evidence-based marketing practices in the food and beverage industry.

Both companies are expected to respond to the notices with appropriate scientific documentation or risk potential penalties under the Food Safety and Standards Act. The outcome of this case may set precedents for how infant nutrition companies substantiate their health claims in the Indian market.